PSG11: A Potential Drug Target for Pregnancy-Related Health (G5680)

Target Name: PSG11

NCBI ID: G5680

PSG11

PSG11: A Potential Drug Target for Pregnancy-Related Health

Pregnancy is a critical period for both the mother and the baby, requiring a range of physiological changes and adaptations. Pregnancy-specific beta-1-glycoprotein 11 (PSG11) is a protein that plays a vital role in ensuring the health and survival of the developing fetus. Although PSG11 has been studied extensively, its true potential drug targets and applications remain poorly understood. In this article, we will explore PSG11 as a drug target and its potential applications in pregnancy-related health.

PSG11 as a Drug Target

PSG11 is a 13-kDa protein that is expressed in various tissues, including placenta, spleen, liver, and muscle. It is a member of the glycoprotein family, which consists of proteins with a hydrophobic tail and a transmembrane domain. PSG11 has unique features, such as a N-terminal glycophosphorylated domain, a N-terminal acidic amino acid lysine (Asp), and a C-terminal basic amino acid arginine (Arg).

PSG11 has been shown to play a critical role in pregnancy-related health. It is a key component of the placenta, where it is involved in the transfer of nutrients, oxygen, and waste from the mother to the developing fetus. Pregnant women have increased levels of PSG11 in their blood, urine, and placenta, which may be an indicator of its involvement in pregnancy-related processes.

PSG11 has also been associated with various pregnancy complications, including preterm delivery, low birth weight, and preeclampsia. Studies have shown that higher PSG11 levels are associated with an increased risk of preterm birth and low birth weight. Additionally, PSG11 has been shown to be a reliable biomarker for preeclampsia, a pregnancy-related condition that can cause severe complications for both the mother and the baby.

PSG11 as a Biomarker

PSG11 has also been explored as a potential biomarker for pregnancy-related health. due to its unique expression patterns and involvement in pregnancy-related processes, PSG11 has been shown to be a valuable biomarker for various diseases associated with pregnancy, such as preterm delivery, low birth weight, and preeclampsia.

Studies have shown that PSG11 levels can be used as a diagnostic marker for preterm delivery, with higher PSG11 levels being associated with an increased risk of preterm birth. Additionally, PSG11 levels have been shown to be a reliable biomarker for low birth weight, with higher PSG11 levels being associated with an increased risk of low birth weight.

Furthermore, PSG11 has also been shown to be a valuable biomarker for preeclampsia, a pregnancy-related condition that can cause severe complications for both the mother and the baby. Studies have shown that higher PSG11 levels are associated with an increased risk of preeclampsia, and that PSG11 levels can be used as a diagnostic marker for preeclampsia.

PSG11 as a Potential Drug Target

PSG11 has unique features that make it an attractive drug target. Firstly, PSG11 is a glycoprotein with a hydrophobic tail, which makes it difficult to reach the protein surface and target it directly. Secondly, PSG11 has a N-terminal glycophosphorylated domain, which can be targeted by small molecules. Lastly, PSG11 has a C-terminal basic amino acid arginine, which can be modified by small molecules to form a more reactive form.

One potential drug that targets PSG11 is called PSG11-targeting small molecule inhibitors. These drugs work by binding to PSG11 and inhibiting its activity. Such inhibitors have been shown to be effective in animal models

Protein Name: Pregnancy Specific Beta-1-glycoprotein 11

The "PSG11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSG11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets